242 related articles for article (PubMed ID: 34645786)
21. Intranasal oxytocin in a genetic animal model of autism.
Szabó J; Mlynár M; Feješ A; Renczés E; Borbélyová V; Ostatníková D; Celec P
Mol Psychiatry; 2024 Feb; 29(2):342-347. PubMed ID: 38102481
[TBL] [Abstract][Full Text] [Related]
22. Immune activation during pregnancy exacerbates ASD-related alterations in Shank3-deficient mice.
Atanasova E; Arévalo AP; Graf I; Zhang R; Bockmann J; Lutz AK; Boeckers TM
Mol Autism; 2023 Jan; 14(1):1. PubMed ID: 36604742
[TBL] [Abstract][Full Text] [Related]
23. Autism and associated disorders: cannabis as a potential therapy.
Babayeva M; Assefa H; Basu P; Loewy Z
Front Biosci (Elite Ed); 2022 Jan; 14(1):1. PubMed ID: 35320905
[TBL] [Abstract][Full Text] [Related]
24. Repetitive behaviors in the Shank1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context.
Sungur AÖ; Vörckel KJ; Schwarting RK; Wöhr M
J Neurosci Methods; 2014 Aug; 234():92-100. PubMed ID: 24820912
[TBL] [Abstract][Full Text] [Related]
25. Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.
Siani-Rose M; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Feb; 8(1):126-137. PubMed ID: 34874191
[No Abstract] [Full Text] [Related]
26. Communication and social interaction in the cannabinoid-type 1 receptor null mouse: Implications for autism spectrum disorder.
Fyke W; Premoli M; Echeverry Alzate V; López-Moreno JA; Lemaire-Mayo V; Crusio WE; Marsicano G; Wöhr M; Pietropaolo S
Autism Res; 2021 Sep; 14(9):1854-1872. PubMed ID: 34173729
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
Fyke W; Alarcon JM; Velinov M; Chadman KK
Autism Res; 2021 Jul; 14(7):1375-1389. PubMed ID: 33886158
[TBL] [Abstract][Full Text] [Related]
28. 5-aminoisoquinolinone attenuates social behavior deficits and immune abnormalities in the BTBR T
Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Alqahtani F; Alhoshani AR; Alasmari F; Alsaleh NB; Attia SM
Pharmacol Biochem Behav; 2020 Feb; 189():172859. PubMed ID: 31982447
[TBL] [Abstract][Full Text] [Related]
29. Influence of maternal zinc supplementation on the development of autism-associated behavioural and synaptic deficits in offspring Shank3-knockout mice.
Vyas Y; Lee K; Jung Y; Montgomery JM
Mol Brain; 2020 Aug; 13(1):110. PubMed ID: 32758248
[TBL] [Abstract][Full Text] [Related]
30. Dietary zinc supplementation rescues fear-based learning and synaptic function in the Tbr1
Lee K; Jung Y; Vyas Y; Skelton I; Abraham WC; Hsueh YP; Montgomery JM
Mol Autism; 2022 Mar; 13(1):13. PubMed ID: 35303947
[TBL] [Abstract][Full Text] [Related]
31. Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ
Kitagawa K; Matsumura K; Baba M; Kondo M; Takemoto T; Nagayasu K; Ago Y; Seiriki K; Hayata-Takano A; Kasai A; Takuma K; Hashimoto R; Hashimoto H; Nakazawa T
Mol Brain; 2021 Mar; 14(1):56. PubMed ID: 33726803
[TBL] [Abstract][Full Text] [Related]
32. Chronic sodium bromide treatment relieves autistic-like behavioral deficits in three mouse models of autism.
Derieux C; Léauté A; Brugoux A; Jaccaz D; Terrier C; Pin JP; Kniazeff J; Le Merrer J; Becker JAJ
Neuropsychopharmacology; 2022 Aug; 47(9):1680-1692. PubMed ID: 35418620
[TBL] [Abstract][Full Text] [Related]
33. Diminished social interaction incentive contributes to social deficits in mouse models of autism spectrum disorder.
Rein B; Yan Z; Wang ZJ
Genes Brain Behav; 2020 Jan; 19(1):e12610. PubMed ID: 31602784
[TBL] [Abstract][Full Text] [Related]
34. Citalopram attenuates social behavior deficits in the BTBR T
Cai Y; Wang L; Nalvarte I; Xiao R; Li X; Fan X
Brain Res Bull; 2019 Aug; 150():75-85. PubMed ID: 31047973
[TBL] [Abstract][Full Text] [Related]
35. A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
Quillet JC; Siani-Rose M; McKee R; Goldstein B; Taylor M; Kurek I
Sci Rep; 2023 Aug; 13(1):13022. PubMed ID: 37608004
[TBL] [Abstract][Full Text] [Related]
36. Developmental social communication deficits in the Shank3 rat model of phelan-mcdermid syndrome and autism spectrum disorder.
Berg EL; Copping NA; Rivera JK; Pride MC; Careaga M; Bauman MD; Berman RF; Lein PJ; Harony-Nicolas H; Buxbaum JD; Ellegood J; Lerch JP; Wöhr M; Silverman JL
Autism Res; 2018 Apr; 11(4):587-601. PubMed ID: 29377611
[TBL] [Abstract][Full Text] [Related]
37. Shank3 mutation in a mouse model of autism leads to changes in the S-nitroso-proteome and affects key proteins involved in vesicle release and synaptic function.
Amal H; Barak B; Bhat V; Gong G; Joughin BA; Wang X; Wishnok JS; Feng G; Tannenbaum SR
Mol Psychiatry; 2020 Aug; 25(8):1835-1848. PubMed ID: 29988084
[TBL] [Abstract][Full Text] [Related]
38. Hypothesis-driven investigations of diverse pharmacological targets in two mouse models of autism.
Rhine MA; Parrott JM; Schultz MN; Kazdoba TM; Crawley JN
Autism Res; 2019 Mar; 12(3):401-421. PubMed ID: 30653853
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
[TBL] [Abstract][Full Text] [Related]
40. Epothilone D Modulates Autism-like Behaviors in the BTBR Mouse Model of Autism Spectrum Disorder.
Zhao M; Chang Q; Yang H; Wang M; Liu Y; Lv N; Lei Q; Wei H
Neuroscience; 2022 May; 490():171-181. PubMed ID: 35227832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
